IPSEF - Exelixis Inc.: Time To Buy
Recently, Japan’s Ministry of Health, Labor and Welfare approved the company’s collaborating product MINNERBO with Daiichi Sankyo’s (OTCPK: OTCPK:DSKYF) for the treatment of hypertension and Exelixis will receive $20 million. In addition, in December, Exelixis (EXEL) in collaboration with Ipsen (OTCPK: OTCPK:IPSEF) has initiated a phase 3 pivotal trial of their lead product CABOMETYX in combination with TECENTRIQ versus sorafenib which is inefficacy in untreated hepatocellular.
Exelixis Inc. (EXEL) is a biotechnology firm headquartered in the San-Francisco that focuses on the finding and developing of therapies for thyroid cancer